Author Index

Adriaanse, H. *see* Agterberg, M., 85, 438
African Regional Study Group *see* Kiire, C.F., S107
Agterberg, M., Adriaanse, H., Lankhof, H., Meloen, R. and Tommassen, J. Outer membrane PhoE protein of *Escherichia coli* as a carrier for foreign antigenic determinants: immunogenicity of epitopes of foot-and-mouth disease virus, 85
Agterberg, M., Adriaanse, H., Barteling, S., van Maanen, K. and Tommassen, J. Protection of guinea-pigs against foot-and-mouth disease virus by immunization with a PhoE–FMDV hybrid protein, 438
Ahl, R. *see* Berger, H.G., 213
Ahmed, M.R. *see* Clemens, J.D., 469
Ahmed, Z.U., Sarker, M.R. and Sack, D.A. Protection of adult rabbits and monkeys for lethal shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of *Shigella flexneri* Y., 153
Ahuja, S. *see* Bhandari, S.K., 105
Ahuja, S. *see* Gupta, R.K., 289, 563
Aizawa, C. *see* Hirabayashi, Y., 243
Aizawa, C. *see* Tamura. S-I., 479
Alcazar, J.M. *see* Bruguera, M., S47
Alexandrova, G.I. *see* Obrosova-Serova, N.P., 57
Alexandrova, G.I., Maassab, H.F., Kendal, A.P., Medvedeva, T.E., Egorov, A.Y., Klimov, A.I. and Cox, N.J. Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates, 61
Allison, A.C. *see* Byars, N.E., 49
Alomar, P. *see* Gonzalez, M.L., 402
Althaus, B. *see* Cryz Jr, S.J., 577
Ambrosch, F. *see* Wiedermann, G., 581
Andersen, A. *see* Buzoni-Gatel, D., 342
Andersen, T.T. *see* Goodman-Snitkoff, G., 257
Anderson, P.M. *see* Mbawuike, I.N., 347
Andre, F.E. *see* Wiedermann, G., 581
Andre, F.E. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine, S74
Anstey, N. *see* Stanford, J.L., 525
Arrowsmith, A.E.M. *see* Samuel, A.R., 390
Artois, M. *see* Brochier, B., 101
Arya, S.C. Efficacy of future formulations of Ty 21a *Salmonella typhi* vaccines in endemic areas, 612
Arya, S.C. Non-immunological facets of poliovirus vaccines, 179
Arya, S.C. Poliomyelitis serosurveillance and immunization for elderly people in otherwise efficiently immunized areas, 514
Arya, S.C. Scientific immune response to vaccines in humans through stimulation of the common mucosal immune system, 613
Arya, S.C. Rabies antibody profile among pregnant females administered therapeutic postexposure vaccine during pregnancy, their neonates and infants, 410
Asian Regional Study Group *see* Sung, J.L., S95
Atmar, R.L., Bloom, K., Keitel, W., Couch, R.B. and Greenberg, S.B. Effect of live attenuated, cold recombinant (CR) influenza virus vaccines in pulmonary function in healthy and asthmatic adults, 217
Audibert, F. *see* Jolivet, M., 35
Azad, A.A. *see* Macreadie, I.G., 549
Azuma, I. *see* Iida, J., 376
Azuma, I. *see* Maeda, H., 237

Babb, C.J. *see* West, D.J., 111
Babuik, L.A. *see* van Drunen Little-van den Hurk S., 358
Bahnemann, H.G. Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine, 299
Bahr, G.A. *see* Stanford, J.L., 525
Balayan, M.S. *see* Kusov, Y.Y., 513
Bancroft, W.H., Kelley, P.W. and Takafuji, E.T. The military and hepatitis B, S33
Banks, S.M. *see* Murphy, B.R., 497
Barber, B.H. *see* Carayanniotis, G., 137
Barteling, S. *see* Agterberg, M., 438
Barrett, A.D.T., *see* Gibson, C.A., 590
Barth, R., Franke, V., Muller, H. and Wienmann, W. Purified chick-embryo-cell(PCEC) rabies vaccine: its potency performance in different test systems and in humans, 41
Bauduin, B. *see* Brochier, B., 101
Bebesheva, N.I. *see* Obrosova-Serova, N.P., 57
Beckenbauer, W.H. *see* Gerber, J.D., 536
Beckenbauer, W.H. *see* Haffer, K.N., 12
Beer, J. *see* Linde, K., 278
Begg, N. and Miller, E. Role of epidemiology in vaccine policy, 180
Beljaev, A.L. *see* Obrosova-Serova, N.P., 57
Bergamini, F. *see* Zanetti, A.R., 205
Berger, H.G., Straub, O.C., Ahl, R., Tesar, M. and Marquadt, O. Identification of foot-and-mouth disease virus replication in vaccinated cattle by antibodies to non-structural virus proteins, 213
Berger, R. *see* Scheiermann, N., S44
Berman, S. *see* Schultz, C.L., 115
Bernard, F. *see* Buzoni-Gatel, D., 342
Bhandari, S.K., Gupta, R.K., Sharma, S.B., Pandey, K., Maheshwari, S.C., Ahuja, S. and Saxena, S.N. Testing of adsorbed diphtheria-pertussis-tetanus (DPT) vaccine for freedom from abnormal toxicity, 105
Black, R.E., Levine, M.E., Ferreccio, C., Clements, M.L., Lanata, C., Rooney, J., Germanier, R. and Chilean Typhoid Committee. Efficacy of one or two doses of Ty21a *Salmonella typhi* vaccine in enteric-coated capsules in a controlled field trial, 81
Blancou, J. *see* Brochier, B., 101
Bloom, K. *see* Atmar, R.L., 217
Blumberg, B.S. Prospects for eradication of hepatitis B virus: introduction, S5
Blumberg, B.S., Prospects for eradication of hepatitis B virus: concluding remarks, S139
Blumberg, B.S., Millman, I., Venkateswaran, P.S. and Thyagarajan, S.P. Hepatitis B virus and primary hetatocellular carcinoma: treatment of HBV carriers with *Phyllanthus amarus*, S86
Bock, H.L., Klockmann, U., Jungst, C., Schindel-Kunzel, F., Theobald, K. and Zerban, R. A new vaccine against tick-borne encephalitis: initial trial in man including a dose response study, 22
Bondarenko, V. *see* Linde, K., 25, 278
Borain, F.E. *see* Clark, H. F., 327
Bosseray, N. and Plommet, M. *Brucella suis* S2, *Brucella melitensis* Rev.1 and *Brucella abortus* S19 living vaccines: residual virulence and immunity induced against three *Brucella* species challenge strains in mice, 462
Bottiger, M. Polio immunity to killed vaccine: an 18-year follow-up, 443
Bourdil, C. *see* Coursaget, P., S15
Bratoyeva, M. *see* Linde, K., 25, 30
Briand, J.P. *see* Muller, S., 308
Brochier, B., Thomas, I., Bauduin, B., Leveau, T., Pastoret, P-P., Languet, B., Chappuis, G., Desmettre, P., Blancou, J. and Artois, M. Use of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies, 101
Brown, G.W. *see* West, D.J., 111
Bruguera, M., Rodicio, J.L., Alcazar, J.M., Oliver, A., Del Rio, G. and Esteban-Mur, G. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients, S47
Buisson, Y. *see* Coursaget, P., S15
Buzoni-Gatel, D., Bernard, F., Andersen, A. and Rodolakis, A. Protective effect of polyclonal and monoclonal antibodies against abortion in mice infected by *Chlamydia psittaci*, 342
Byars, N.E., Allison, A.C., Harmon, M.W. and Kendal, A.P. Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation, 49

Author Index

Adriaanse, H. *see* Agterberg, M., 85, 438
African Regional Study Group *see* Kiire, C.F., S107
Agterberg, M., Adriaanse, H., Lankhof, H., Meloen, R. and Tommassen, J. Outer membrane PhoE protein of *Escherichia coli* as a carrier for foreign antigenic determinants: immunogenicity of epitopes of foot-and-mouth disease virus, 85
Agterberg, M., Adriaanse, H., Barteling, S., van Maanen, K. and Tommassen, J. Protection of guinea-pigs against foot-and-mouth disease virus by immunization with a PhoE–FMDV hybrid protein, 438
Ahl, R. *see* Berger, H.G., 213
Ahmed, M.R. *see* Clemens, J.D., 469
Ahmed, Z.U., Sarker, M.R. and Sack, D.A. Protection of adult rabbits and monkeys for lethal shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of *Shigella flexneri* Y., 153
Ahuja, S. *see* Bhandari, S.K., 105
Ahuja, S. *see* Gupta, R.K., 289, 563
Aizawa, C. *see* Hirabayashi, Y., 243
Aizawa, C. *see* Tamura. S-I., 479
Alcazar, J.M. *see* Bruguera, M., S47
Alexandrova, G.I. *see* Obrosova-Serova, N.P., 57
Alexandrova, G.I., Maassab, H.F., Kendal, A.P., Medvedeva, T.E., Egorov, A.Y., Klimov, A.I. and Cox, N.J. Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates, 61
Allison, A.C. *see* Byars, N.E., 49
Alomar, P. *see* Gonzalez, M.L., 402
Althaus, B. *see* Cryz Jr, S.J., 577
Ambrosch, F. *see* Wiedermann, G., 581
Andersen, A. *see* Buzoni-Gatel, D., 342
Andersen, T.T. *see* Goodman-Snitkoff, G., 257
Anderson, P.M. *see* Mbawuike, I.N., 347
Andre, F.E. *see* Wiedermann, G., 581
Andre, F.E. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine, S74
Anstey, N. *see* Stanford, J.L., 525
Arrowsmith, A.E.M. *see* Samuel, A.R., 390
Artois, M. *see* Brochier, B., 101
Arya, S.C. Efficacy of future formulations of Ty 21a *Salmonella typhi* vaccines in endemic areas, 612
Arya, S.C. Non-immunological facets of poliovirus vaccines, 179
Arya, S.C. Poliomyelitis serosurveillance and immunization for elderly people in otherwise efficiently immunized areas, 514
Arya, S.C. Scientific immune response to vaccines in humans through stimulation of the common mucosal immune system, 613
Arya, S.C. Rabies antibody profile among pregnant females administered therapeutic postexposure vaccine during pregnancy, their neonates and infants, 410
Asian Regional Study Group *see* Sung, J.L., S95
Atmar, R.L., Bloom, K., Keitel, W., Couch, R.B. and Greenberg, S.B. Effect of live attenuated, cold recombinant (CR) influenza virus vaccines in pulmonary function in healthy and asthmatic adults, 217
Audibert, F. *see* Jolivet, M., 35
Azad, A.A. *see* Macreadie, I.G., 549
Azuma, I. *see* Iida, J., 376
Azuma, I. *see* Maeda, H., 237

Babb, C.J. *see* West, D.J., 111
Babuik, L.A. *see* van Drunen Little-van den Hurk S., 358
Bahnemann, H.G. Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine, 299
Bahr, G.A. *see* Stanford, J.L., 525
Balayan, M.S. *see* Kusov, Y.Y., 513
Bancroft, W.H., Kelley, P.W. and Takafuji, E.T. The military and hepatitis B, S33
Banks, S.M. *see* Murphy, B.R., 497
Barber, B.H. *see* Carayanniotis, G., 137
Barteling, S. *see* Agterberg, M., 438
Barrett, A.D.T., *see* Gibson, C.A., 590
Barth, R., Franke, V., Muller, H. and Wienmann, W. Purified chick-embryo-cell(PCEC) rabies vaccine: its potency performance in different test systems and in humans, 41
Bauduin, B. *see* Brochier, B., 101
Bebesheva, N.I. *see* Obrosova-Serova, N.P., 57
Beckenbauer, W.H. *see* Gerber, J.D., 536
Beckenbauer, W.H. *see* Haffer, K.N., 12
Beer, J. *see* Linde, K., 278
Begg, N. and Miller, E. Role of epidemiology in vaccine policy, 180
Beljaev, A.L. *see* Obrosova-Serova, N.P., 57
Bergamini, F. *see* Zanetti, A.R., 205
Berger, H.G., Straub, O.C., Ahl, R., Tesar, M. and Marquadt, O. Identification of foot-and-mouth disease virus replication in vaccinated cattle by antibodies to non-structural virus proteins, 213
Berger, R. *see* Scheiermann, N., S44
Berman, S. *see* Schultz, C.L., 115
Bernard, F. *see* Buzoni-Gatel, D., 342
Bhandari, S.K., Gupta, R.K., Sharma, S.B., Pandey, K., Maheshwari, S.C., Ahuja, S. and Saxena, S.N. Testing of adsorbed diphtheria-pertussis-tetanus (DPT) vaccine for freedom from abnormal toxicity, 105
Black, R.E., Levine, M.E., Ferreccio, C., Clements, M.L., Lanata, C., Rooney, J., Germanier, R. and Chilean Typhoid Committee. Efficacy of one or two doses of Ty21a *Salmonella typhi* vaccine in enteric-coated capsules in a controlled field trial, 81
Blancou, J. *see* Brochier, B., 101
Bloom, K. *see* Atmar, R.L., 217
Blumberg, B.S. Prospects for eradication of hepatitis B virus: introduction, S5
Blumberg, B.S., Prospects for eradication of hepatitis B virus: concluding remarks, S139
Blumberg, B.S., Millman, I., Venkateswaran, P.S. and Thyagarajan, S.P. Hepatitis B virus and primary hetatocellular carcinoma: treatment of HBV carriers with *Phyllanthus amarus*, S86
Bock, H.L., Klockmann, U., Jungst, C., Schindel-Kunzel, F., Theobald, K. and Zerban, R. A new vaccine against tick-borne encephalitis: initial trial in man including a dose response study, 22
Bondarenko, V. *see* Linde, K., 25, 278
Borain, F.E. *see* Clark, H. F., 327
Bosseray, N. and Plommet, M. *Brucella suis* S2, *Brucella melitensis* Rev.1 and *Brucella abortus* S19 living vaccines: residual virulence and immunity induced against three *Brucella* species challenge strains in mice, 462
Bottiger, M. Polio immunity to killed vaccine: an 18-year follow-up, 443
Bourdil, C. *see* Coursaget, P., S15
Bratoyeva, M. *see* Linde, K., 25, 30
Briand, J.P. *see* Muller, S., 308
Brochier, B., Thomas, I., Bauduin, B., Leveau, T., Pastoret, P-P., Languet, B., Chappuis, G., Desmettre, P., Blancou, J. and Artois, M. Use of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies, 101
Brown, G.W. *see* West, D.J., 111
Bruguera, M., Rodicio, J.L., Alcazar, J.M., Oliver, A., Del Rio, G. and Esteban-Mur, G. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients, S47
Buisson, Y. *see* Coursaget, P., S15
Buzoni-Gatel, D., Bernard, F., Andersen, A. and Rodolakis, A. Protective effect of polyclonal and monoclonal antibodies against abortion in mice infected by *Chlamydia psittaci*, 342
Byars, N.E., Allison, A.C., Harmon, M.W. and Kendal, A.P. Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation, 49

Carayanniotis, G. and Barber, B.H. Characterization of the adjuvant-free serological response to antigens coupled to antibodies specific for class II MHC determinants, 137
Caudrelier, P. *see* Lahrech, M.T., 306
Chakraborty, J. *see* Clemens, J.D., 469
Chambon, P. *see* Meneguizzi, G., 199
Chanock, R.M. *see* Collins, P.L., 164
Chapman, A. *see* Macreadie, I.G., 549
Chappuis, G. *see* Brochier, B., 101
Charbit, A. *see* van der Werf, S., 269
Chedid, L. *see* Jolivet, M., 35
Chiron, J.P. *see* Coursaget, P., 815
Chitinand, S. *see* Poovorawan, Y., 856
Cho, H.J. *see* Jericho, K.W.F., 315
Chotard, J. *see* Coursaget, P., 815
Christensen, P. *see* Stjernquist-Desatnik, A., 150
Christianson, K.K. *see* Gerber, J.D., 536
Chumdermpadetsuk, S. *see* Poovorawan, Y., 856
Clark, H.F., Borain, F.E., Modesto, K. and Plotkin, S.A. Serotype 1 reassortant of bovine rotavirus WC3, strain W179-9, induces a polytypic antibody response in infants, 327
Clemens, J.D., Sack, D.A., Chakraborty, J., Rao, F., Ahmed, M.R., Harris, J.R., van Loon, M.R., Khan, F., Yunis, S., Huda, M., Kay, B.A., Svennerholm, A-M. and Holmgren, J. Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines, 469
Clements, M.L. *see* Black, R.E., 81
Collins, P.L., Purchell, R.H., London, W.T., Lawrence, L.A., Chanock, R.M. and Murphy, B.R. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus, 164
Cook, R.F., O'Neill, T., Strachan, E., Sundquist, B. and Mumford, J.A. Protection against lethal equine herpes virus type 1 (subtype 1) infection in hamsters by immune stimulating complexes (ISCOMs) containing the major viral glycoproteins, 491
Cope, J. AIDS vaccine research in the UK, 3
Couch, R.B. *see* Atmar, R.L., 217
Coupland, B., Revill, S. and Desselberger, U. Relation between susceptibility to rubellavirus infection in pregnant women and decreased immune responsiveness, 190
Coursaget, P., Yvonnet, B., Bourdil, C., Buisson, Y., Chotard, J., N'Doye, R., Molinie, C., Diop-Mar, I. and Chiron, J.P. Hepatitis B surface antigen reactivity in man due to a new variant of hepatitis B virus, S15
Cox, N.J. *see* Alexandrova, G.I., 61
Cryz Jr, S.J., Levine, M.M., Kaper, J.B., Furer, E. and Althaus, B. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults, 577
Cryz, S.J. *see* Herrington, D.A., 353
Cuzin, F. *see* Meneguizzi, G. 199

D'Hondt, E. *see* Wiedermann, G., 581
Dechert, G. *see* Fescharek, R., 409
Deepen, R. *see* Gerlich, W.H., S63
Del Rio, G. *see* Bruguera, M., S47
Delem, A. *see* Wiedermann, G., 581
Dentchev, V. *see* Linde, K., 25
Derr, J.T. *see* Haffer, K.N., 12
Desmettre, P. *see* Brochier, B., 101
Desselberger, U. *see* Coupland, B., 190
Diop-Mar, I. *see* Coursaget, P., 815
Doel, T.R. and Pullen, L. International bank for foot-and-mouth disease vaccine: stability studies with virus concentrates and vaccines prepared from them, 473
Dowlati, Y. *see* Stanford, J.L., 525
Dragunsky, E.M.; Rivera, E., Hochstein, H.D. and Levenbrook, I.S. *In vitro* characterization of *Salmonella typhi* mutant strains for live oral vaccines, 263
Drillien, R. *see* Wild, F., 441
Drozdov, S.G. *see* Kusov, Y.Y., 513

Egorov, A.Y. *see* Alexandrova, G.I., 61
Eiesle, L.E. *see* Goodman-Snitkoff, G., 257
Elbert, L.B. *see* Kusov, Y.Y., 513
Enders, G. *see* Schodel, F., 569
Erickson, G.A. *see* Katz, J.B., 286
Erroz, M.J. *see* Gonzalez, M.L., 402
Eskola, J., Kayhty, H., Takala, A., Ronnberg, P-R., Kela, E. and Peltola, H. Reactogenicity and immunogenicity of combined vaccines for bacteraemic diseases caused by *Haemophilus influenzae* type B, meningococci and pneumococci in 24-month-old children, 107
Esteban-Mur, R. *see* Bruguera, M., S47
European Regional Study Group *see* Goudeau, A., S113

Fahey, K.J. *see* Macreadie, I.G., 549
Farrington, C.P. *see* Storsaeter, J., 457
Fay, O.H. and Latin American Regional Study. Hepatitis B in Latin America: epidemiological patterns and eradication strategy, S100
Felix, A.M. *see* Goodman-Snitkoff, G., 257
Ferreccio, C. *see* Black, R.E., 81
Fescharek, R. and Franke, V. Dangers of immunosuppressive treatments in postexposure rabies prophylaxis, 172
Fescharek, R., Quast, U., Maass, G., Merkle, W. and Schwarz, S. Measles–mumps vaccination in the FRG: an empirical analysis after 14 years of use. I. Efficacy and analysis of vaccine failures, 333
Fescharek, R., Quast, U. and Dechert, G. Postexposure rabies vaccination during pregnancy: experience from post-marketing surveillance with 16 patients, 409
Fescharek, R., Quast, U., Maass, G., Merkle, W. and Schwarz, S. Measles–mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects, 446
Flexner, C., Moss, B., London, W.T. and Murphy, B.R. Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2, 17
Fohlman, J., Ilback, N-G., Friman, G. and Morein, B. Vaccination of Balb/C mice against enteroviral mediated myocarditis, 381
Formal, S.B. *see* Herrington, D.A., 353
Forrest, B.D., Shearman, D.J.C. and LaBrooy, J.T. Specific immune response in humans following rectal delivery of typhoid vaccine, 209
Forzani, I. *see* Rizzetto, M., 810
Franke, V. *see* Barth, R., 41
Franke, V. *see* Fescharek, R., 172
Friman, G. *see* Fohlman, J., 381
Fuerst, T.R. *see* Goodman-Snitkoff, G., 257
Fujisawa, Y., Kuroda, S-I., Van Eerd, P.M.C.A., Schellekens, H. and Kakinuma, A. Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2+S) protein particles (a third generation vaccine), 192
Funato, H. *see* Hirabayashi, Y., 243
Funato, H. *see* Tamura, S-I., 479
Furer, E. *see* Cryz Jr, S.J., 577

Ganapati, R. *see* Stanford, J.L., 525
Gast, A.M. *see* Gerber, J.D., 536
Gast, G. *see* see Masihi, K.N., 159
Gerber, J.D., Ingersoll, J.D., Gast, A.M., Christianson, K.K., Selzer, N.L., Landon, R.M., Pfeiffer, N.E., Sharpes, R.L. and Beckenbauer, W.H. Protection against feline infectious peritonitis by intranasal inoculation of a temperature sensitive FIPV vaccine, 536
Gerlich, W.H., Deepen, R., Heermann, K-H., Krone, B., Lu, X-Y., Seifer, M. and Thomssen, R. Protective potential of hepatitis B virus antigens other than the S gene protein, S63
Germanier, R. *see* Black, R.E., 81
Gesemann, M. *see* Scheiermann, N., S44
Ghazi Saidi, K. *see* Stanford, J.L., 525
Ghendon, Y. WHO strategy for the global elimination of new cases of hepatitis B, S129
Gibson, C.A., Willis, M.R., Gould, E.A., Sanders, P.G. and Barrett, A.D.T. Effect of administration of sodium aurothiomalate on the virulence of yellow fever viruses in adult mice, 590
Gifford, G.A. *see* van Drunen Little-van den Hurk, S., 358

Girard, M. *see* van der Werf, S., 269
Giraudon, P. *see* Wild, F., 441
Goilav, C. *see* Piot, P., 837
Goilav, C., Prinsen, H. and Piot, P. Protective efficacy of a recombinant DNA vaccine against hepatitis B in male homosexuals: results at 36 months, S50
Gonczol, E., Ianacone, J., Ho, W., Meignier, B. and Plotkin, S. Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers, 130
Gonzalez, M.L., Usandizaga, M., Alomar, P., Salva, F., Martin, F., Erroz, M.J. and Lardinois, R. Intradermal and intramuscular route for vaccination against hepatitis B, 402
Goodman-Snitkoff, G., Eiesle, L.E., Heimer, E.P., Felix, A.M., Andersen, T.T., Fuerst, T.R. and Mannino, R.J. Defining minimal requirements for antibody production to peptide antigens, 257
Gotoh, H. *see* Ogawa, R., 486
Goudeau, A. and European Regional Study Group. Epidemiology and eradication strategy for hepatitis B in Europe, S113
Gould, E.A. *see* Gibson, C.A., 590
Gras-Masse, H. *see* Jolivet, M., 35
Greenberg, S.B. *see* Atmar, R.L., 217
Gupta, R.K. Pertussis vaccine controversy, 172
Gupta, R.K. *see* Bhandari, S.K., 105
Gupta, R.K., Saxena, S.N., Sharma, S.B. and Ahuja, S. Immunogenicity of glutaraldehyde inactivated pertussis vaccine, 563
Gupta, R.K., Saxena, S.N., Sharma, S.B. and Ahuja, S. Protection of mice inoculated with purified pertussis toxin and filamentous haemagglutinin against intracerebral challenge with live *Bordetella pertussis*, 289
Gupta, R.K. Use of glutaraldehyde for the preparation of pertussis vaccine, 409

Hackett, J. *Salmonella*-based vaccines, 5
Hadler, S.C. Hepatitis B virus infection and health care workers, S24
Haffer, K.N., Keortje, W.D., Derr, J.T. and Beckenbauer, W.H. Evaluation of immunosuppressive effect and efficacy of an improved-potency feline leukaemia vaccine, 12
Hale, T.L. *see* Herrington, D.A., 353
Hallander, H. *see* Storsaeter, J., 457
Hamilton, D. *see* Schultz, C.L., 115
Harmon, M.W. *see* Byars, N.E., 49
Harmon, N.W. *see* Obrosova-Servoa, N.P., 57
Harris, J.R. *see* Clemens, J.D., 469
Hartman, A. *see* Schultz, C.L., 115
Hasegawa, A. *see* Maeda, H., 237
Heckels, J.E., Virji, M. and Tinsley, C.R. Vaccination against gonorrhoea: the potential protective effect of immunization with a synthetic peptide containing a conserved epitope of gonococcal membrane protein IB, 225
Heerman, K-H. *see* Gerlich, W.H., 863
Heimer, E.P. *see* Goodman-Snitkoff, G., 257
Heine, H-G. *see* Macreadie, I.G., 549
Henderson, L.M. *see* Katz, J.B., 286
Henrickson, K.J. and Portner, A. Antibody response in children to antigenic sites on human PIV-3 HN: correlation with known epitopes mapped by monoclonal antibodies, 75
Herrington, D.A., Van de Verg, L., Formal, S.B., Hale, T.L., Tall, B.D., Cryz, S.J., Tramont, E.C. and Levine, M. Studies in volunteers to evaluate candidate *Shigella* vaccines: Further experience with a bivalent *Salmonella typhi–Shigella sonnei* vaccine and protection conferred by previous *Shigella sonnei* disease, 353
Himanen, J-P., Taira, S., Sarvas, M., Saris, P. and Runeberg-Nyman, K. Expression of pertussis toxin subunit S4 as an intracytoplasmic protein in *Bacillus subtilis*, 600
Hirabayashi, Y. *see* Tamura, S-I., 479
Hirabayashi, Y., Kurata, H., Funato, H., Nagamine, T., Aizawa, C., Tamura, S., Shimada, K. and Kurata, T. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination, 243
Hishiyama, M. *see* Yamada, A., 553
Ho, W. *see* Gonczol, E., 130
Hochstein, H.D. *see* Dragunsky, E.M., 263
Hofmann, H. *see* Wiedermann, G., 581
Hofnung, M. *see* van der Werf, S., 269
Hollinger, F.B. and North American Regional Study. Controlling hepatitis B virus transmission in North America, S122
Holmgren, J. *see* Clemens, J.D., 469
Honda, T. *see* Oka, T., 573
Huchschorn, P. *see* Masihi, K.N., 159
Huda, M. *see* Clemens, J.D., 469

Ianacone, J. *see* Gonczol, E., 130
Iida, J., Ishihara, C., Mizukoshi, N., Kitoh, K., Tsukidate, K., Katsu, K., Toyosawa, T. and Azuma, I. Prophylactic activity of dihydroheptaprenol, a synthetic polyprenol derivative, against Sendai virus infection in mice, 376
Ilback, N-G. *see* Fohlman, J., 381
Ingersoll, J.D. *see* Gerber, J.D., 536
Inoue, A. *see* Nerome, K., 503
Iritani, Y. *see* Ogawa, R., 486
Ishida, M. *see* Nerome, K., 503
Ishihara, C. *see* Iida, J., 376
Ishizaka, S., Yoshikawa, M., Kitagami, K. and Tsujii, T. Oral adjuvants for viral vaccines in humans, 337
Iyisan, S. *see* Mulcahy, G., 249

Jagadish, M.N. *see* Macreadie, I.G., 549
Jager, E.J. *see* Kusters, J.G., 605
Jayakumar, R. and Ramadass, P. Studies on cell-mediated immune response to rabies virus immunization in dogs, 304
Jericho, K.W.F., Cho, H.J. and Kozub, G.C. Protective effect of inactivated *Pasteurella haemolytica* bacterin challenged in bovine herpesvirus-1 experimentally infected calves, 315
Joffret, M-L., Morgeaux, S., Leclerc, C., Oth, D., Zanetti, C., Sureau, P. and Perrin, P. Enhancement of interleukin-2 activity by liposomes, 385
Jolivet, M., Lise, L., Gras-Masse, H., Tartar, A., Audibert, F. and Chedid, L. Polyvalent synthetic vaccines: relationship between T epitopes and immunogenicity, 35
Jung, M-C. *see* Schodel, F., 569
Jungst, C. *see* Bock, H.L., 22
Just, M. *see* Scheiermann, N., 844

Kakinuma, A. *see* Fujisawa, Y., 192
Kamogawa, K. *see* Ogawa, R., 486
Kane, M.A. *see* Margolis, H.S., 881
Kantele, A. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine, 321
Kaper, J.B. *see* Cryz Jr, S.J., 577
Kapikian, A.Z. *see* Tajima, T., 70
Kar, A. *see* Talwar, G.P., 121
Kataoka, T. *see* Nerome, K., 503
Katsu, K. *see* Iida, J., 376
Katz, J.B., Henderson, L.M. and Erickson, G.A. Recombination *in vivo* of pseudorabies vaccine strains to produce new virus strains, 286
Kaufman, B. *see* Schultz, C.L., 115
Kay, B.A. *see* Clemens, J.D., 469
Kayhty, H. *see* Eskola, J., 107
Kazachkov, Y.A. *see* Kusov, Y.Y., 513
Kegels, E. *see* Piot, P., 837
Keitel, W. *see* Atmar, R.L., 217
Kela, E. *see* Eskola, J., 107
Kelley, P.W. *see* Bancroft, W.H., 833
Kendal, A.P. *see* Byars, N.E., 49
Kendal, A.P. *see* Obrosova-Servoa, N.P., 57
Kendal, A.P. *see* Alexandrova, G.I., 61
Keortje, W.D. *see* Haffer, K.N., 12
Khan, F. *see* Clemens, J.D., 469
Kieny, M.P. *see* Meneguizzi, G., 199
Kiire, C.F. and African Regional Study Group. Hepatitis B infection in sub-Saharan Africa, S107
Kikuta, K. *see* Tamura, S-I., 479
King, J. *see* Tajima, T., 70
Kiso, M. *see* Maeda, H., 237
Kit, S. Genetically engineered vaccines for control of Aujeszky's disease (pseudorabies), 420
Kitagami, K. *see* Ishizaka, S., 337
Kitching, R.P. *see* Samuel, A.R., 390
Kitoh, K. *see* Iida, J., 376
Klimov, A.I. *see* Alexandrova, G.I., 61
Klockmann, U. *see* Bock, H.L., 22
Knowles, N.J. *see* Samuel, A.R., 390
Kodama, K. *see* Ogawa, R., 486
Kollaritsch, H. *see* Wiedermann, G., 581
Komiya, T. *see* Yamaya, S.I., 65
Kondo, Y. *see* Tajima, T., 70
Kozub, G.C. *see* Jericho, K.W.F, 315

Krone, B. *see* Gerlich, W.H., S63
Krutyanskaya, G.L. *see* Kusov, Y.Y., 513
Kunz, C. *see* Wiedermann, G., 581
Kurata, H. *see* Hirabayashi, Y., 243
Kurata, T. *see* Hirabayashi, Y., 243
Kurata, T. *see* Tamura, S-I., 479
Kurl, D.N. *see* Stjernquist-Desatnik, A., 150
Kuroda, S-I. *see* Fujisawa, Y., 192
Kusova, Y.Y., Kazachkov, Y.A., Elbert, L.B., Krutyanskaya, G.L., Poleschuk, V.F., Sobol, A.V., Titova, I.P., Lisitsyna, E.A., Drozdov, S.G. and Balayan, M.S. Characteristics of inactivated hepatitis A vaccine prepared from virus propagated in heteroploid continuous monkey cell line, 513
Kusters, J.G., Jager, E.J., Niesters, H.G.M. and van der Ziejst, B.A.M. Sequence evidence for RNA recombination in field isolates of avian coronavirus IBV, 605

LaBrooy, J.T. *see* Forrest, B.D., 209
Lahrech, M.T. and Caudrelier, P. Immunological response of Moroccan children and newborns to oral poliovirus vaccine prepared on Vero cells, 306
Lair, D. *see* Therien, H-M., 558
Lanata, C. *see* Black, R.E., 81
Landon, R.M. *see* Gerber, J.D., 536
Lange, W. *see* Masihi, K.N., 159
Languet, B. *see* Brochier, B., 101
Lankhof, H. *see* Agterberg, M., 85
Lardinois, R. *see* Gonzalez, M.L., 402
Lathe, R. *see* Meneguizzi, G., 199
Latin American Regional Study *see* Fay, O.H., S100
Lawrence, L.A. *see* Collins, P.L., 164
Lawrence, L.A. *see* Murphy, B.R., 497
Leclerc, C. *see* van der Werf, S., 269
Leclerc, C. *see* Joffret, M-L., 385
Lecocq, J-P., *see* Meneguizzi, G., 199
Lecocq, J.P. *see* Wild, F., 441
Leveau, T. *see* Brochier, B., 101
Levenbrook, I.S. *see* Dragunsky, E.M., 263
Levine, M.E. *see* Black, R.E., 81
Levine, M.M. *see* Cryz Jr, S.J., 577
Levine, M.M. *see* Herrington, D.A., 353
Linde, K., Dentchev, V., Bondarenko, V., Marinova, S., Randhagen, B., Bratoyeva, M., Tsvetanov, Y. and Romanova, Y. Live *Shigella flexneri* 2a and *Shigella sonnei* I vaccine candidate strains with two attenuating markers. I. Construction of vaccine candidate strains with retained invasiveness but reduced intracellular multiplication, 25
Linde, K., Marinova, S., Vassilev, T., Bratoyeva, M. and Linde, K. Live *Shigella flexneri* 2a and *Shigella sonnei* I vaccine candidate strains with two attenuating markers. II. Preliminary results of vaccination of adult volunteers and children aged 2–17 years, 30
Linde, K., Beer, J. and Bondarenko, V. Stable *Salmonella* live vaccine strains with two or more attenuating mutations and any desired level of attenuation, 278
Lise, L. *see* Jolivet, M., 35
Lisitsyna, E.A. *see* Kusov, Y.Y., 513
London, W.T. *see* Flexner, C., 17
London, W.T. *see* Collins, P.L., 164
Lonskaja, N.I. *see* Obrosova-Servoa, N.P., 57
Lu, X-Y. *see* Gerlich, W.H., 863
Lucas, S. *see* Stanford, J.L., 525
Lugosi, L. Analysis of variables of plasmid transformation of a bacterial vaccine: Studies on recombinant BCG, 145

Maass, G: *see* Fescharek, R., 333, 446
Maassab, H.F. *see* Alexandrova, G.I., 61
Macreadie, I.G., Vaughan, P.R., McKern, N.M., Jagadish, M.N., Heine, H-G., Ward, C.W., Chapman, A., Fahey, K.J. and Azad, A.A. Passive protection against infectious bursal disease virus by viral VP2 protein, 549
Maeda, H., Saiki, I., Yamamoto, N., Takahashi, T., Sekiguchi, S., Kiso, M., Hasegawa, A. and Azuma, A. Activation by synthetic lipid A subunit analogues (GLA compounds) of tumoricidal properties in human blood monocytes, 237
Maheshwari, S.C. *see* Bhandari, S.K., 105
Mahoney, R.T. Cost of plasma-derived hepatitis B vaccine production, 397
Mannino, R.J. *see* Goodman-Snitkoff, G., 257
Mao, J. Development of live, attenuated hepatitis A vaccine (H2-strain), 523
Marcuse, E.K. and Wentz, K.R. The NCES reconsidered: a summary of a 1989 workshop, 531
Margolis, H.S., Schats, G.C. and Kane, M.A. Development of recommendations for control of hepatitis B virus infections: the role of cost analysis, S81
Marinova, S. *see* Linde, K., 25, 30
Marquadt, O. *see* Berger, H.G., 213
Martin, F. *see* Gonzalez, M.L., 402
Masek, K. *see* Masihi, K.N., 159
Masihi, K.N., Lange, W., Schwenke, S., Gast, G., Huchshorn, P., Palache, A. and Masek, K. Effect of immunomodulator adamantylamide dipeptide on antibody response to influenza subunit vaccines and protection against aerosol influenza infection, 159
Matuhasi, T. *see* Yamaya, S.I., 65
Maurer, C. *see* Scheiermann, N., S44
Maynard, J.E. Hepatitis B: global importance and need for control, S18
Mbawuike, I.N., Wyde, P.R. and Anderson, P.M. Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes, 347
McKern, N.M. *see* Macreadie, I.G., 549
Medvedeva, T.E. *see* Obrosova-Servoa, N.P., 57
Medvedeva, T.E. *see* Alexandrova, G.I., 61
Meheus, A. *see* Van Damme, P., 853
Meignier, B. *see* Vaux-Peretz, F., 543
Meignier, B. *see* Gonczol, E., 130
Meloen, R. *see* Agterberg, M., 85
Meneguizzi, G., Kieny, M.P., Lecocq, J-P., Chambon, P., Cuzin, F. and Lathe, R. *Vaccinia* recombinants expressing early bovine papilloma virus (BPV1) protines: retardation of BPV1 tumour development, 199
Merkle, W. *see* Fescharek, R., 333, 446
Middle East Regional Study *see* Toukan, A., S117
Miller, E. *see* Begg, N., 180
Miller, E. *see* Storsaeter, J., 457
Millman, I. *see* Blumberg, B.S., 886
Mimic, V. *see* van der Werf, S., 269
Minh Ly, Ho *see* Stanford, J.L., 525
Misra, R.S. *see* Talwar, G.P., 121
Mizugichi, J. *see* Yamaya, S.I., 65
Mizukoshi, N. *see* Iida, J., 376
Modesto, K. *see* Clark, H.F., 327
Molinie, C. *see* Coursaget, P., S15
Mollby, R. *see* Storsaeter, J., 457
Morein, B. *see* Fohlman, J., 381
Morgeaux, S. *see* Joffret, M-L., 385
Moss, B. *see* Flexner, C., 17
Mukherjee, H.K. *see* Talwar, G.P., 121
Muhkerjee, R. *see* Talwar, G.P., 121
Mulcahy, G., Gale, C., Robertson, P., Iyisan, S., DiMarchi, R.D. and Doel, T.R. Isotype responses of infected, virus-vaccinated and peptide-vaccinated cattle to foot-and-mouth disease virus, 249
Muller, H. *see* Barth, R., 41
Muller, S., Plaue, S., Samama, J.P., Valette, M., Briand, J.P. and van Regenmortel, M.H.V. Antigenic properties and protective capacity of a cyclic peptide corresponding to site A of influenza virus haemagglutin, 308
Mumford, J.A. *see* Cook, R.F., 491
Murphy, B.R. *see* Flexner, C., 17
Murphy, B.R. *see* Collins, P.L., 164
Murphy, B.R., Sotnikov, A.V., Lawrence, L.A., Banks, S.M. and Prince, G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization, 497

N'Doye, R. *see* Coursaget, P., S15
Nagamine, T. *see* Hirabayashi, Y., 243
Nagamine, T. *see* Tamura, S-I., 479
Nair, S.K. *see* Talwar, G.P., 121
Nakagawa, M. *see* Tamura, S-I., 479
Nerome, K., Yoshioka, Y., Ishida, M., Okuma, K., Oka, T., Kataoka, T., Inoue, A. and Oya, A. Development of a new type of influenza subunit vaccine made by muramyldipeptide-liposome: enhancement of humoral and cellular immune responses, 503

Niesters, H.G.M. *see* Kusters, J.G., 605
Nonaka, S. *see* Oka, T., 573
North American Regional Study *see* Hollinger, F.B., S122

O'Neill, T. *see* Cook, R.F., 491
Obrosova-Serova, N.P., Slepushkin, A.N., Harmon, N.W., Bebesheva, N.I., Beljaev, A.L., Lonskaja, N.I., Medvedeva, T.E., Kendal, A.P., Peklisova, L.V. and Alexandrova, G.I. Evaluation in children of cold-adapted influenza B live attenuated intranasal vaccine prepared by reassortment between wild-type B/Ann Arbor/1/86 and cold-adapted B/Leningrad/14/55 viruses, 57
Ogawa, R., Yanagida, N., Saeki, S., Saito, S., Ohkawa, S., Gotoh, H., Kodama, K., Kamogawa, K., Sawaguchi, K. and Iritani, Y. Recombinant fowlpox viruses inducing protective immunity against Newcastle disease and fowlpox viruses, 486
Ohkawa, S. *see* Ogawa, R., 486
Ohkuma, K. *see* Oka, T., 573
Oka, T. *see* Nerome, K., 503
Oka, T., Honda, T., Ohkuma, K., Sakoh, M. and Nonaka, S. Influenza vaccine: enhancement of immune response by application of carboxy-vinylpolymer, 573
Okuma, K. *see* Nerome, K., 503
Olin, P. *see* Storsaeter, J., 457
Oliver, A. *see* Bruguera, M., 847
Oth, D. *see* Joffret, M-L., 385
Ouldridge, E.J. *see* Samuel, A.R., 390
Oya, A. *see* Nerome, K., 503

Pal, S.C. *see* Sinha, A.K., 410
Palache, A. *see* Masihi, K.N., 159
Pandey, K. *see* Bhandari, S.K., 105
Pandey, R.M. *see* Talwar, G.P., 121
Parida, N.R. *see* Talwar, G.P., 121
Pastoret, P-P. *see* Brochier, B., 101
Peklisova, L.V. *see* Obrosova-Servoa, N.P., 57
Peltola, H. *see* Eskola, J., 107
Perrin, P. *see* Joffret, M-L., 385
Pfeiffer, N.E. *see* Gerber, J.D., 536
Piot, P. *see* Goilav, C., S50
Piot, P., Goilav, C. and Kegels, E. Hepatitis B: transmission by sexual contact and needle sharing, S37
Plaue, S. *see* Muller, S., 308
Plommet, M. *see* Bosseray, N., 462
Plotkin, S. *see* Gonczol, E., 130
Plotkin, S.A. *see* Clark, H.F., 327
Poleschuk, V.F. *see* Kusov, Y.Y., 513
Pongpunlert, W. *see* Poovorawan, Y., S56
Ponzetto, A. *see* Rizzetto, M., S10
Poovorawan, Y., Sanpavat, S., Pongpunlert, W., Chumdermpadetsuk, S., Sentrakul, P., Chitinand, S., Sakulramrung, R. and Tannirundorn, Y. Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage, S56
Portner, A. *see* Henrickson, K.J., 75
Powell, C. *see* Schultz, C.L., 115
Pozzi, A. *see* Zanetti, A.R., 205
Prince, G.A. *see* Murphy, B.R., 497
Pringle, C.R. *see* Watt, P.J., 231
Prinsen, H. *see* Goilav, C., 850
Pullen, L. *see* Doel, T.R., 473
Purchell, R.H. *see* Collins, P.L., 164

Quast, U. *see* Fescharek, R., 333, 409, 446

Ramadass, P. *see* Jayakumar, R., 304
Ramu, G. *see* Stanford, J.L., 525
Randhagen, B. *see* Linde, K., 25
Rao, F. *see* Clemens, J.D., 469
Revill, S. *see* Coupland, B., 190
Rivera, E. *see* Dragunsky, E.M., 263
Rizzetto, M., Ponzetto, A. and Forzani, I. Hepatitis delta virus as a global health problem, S10
Robertson, P. *see* Mulcahy, G., 249
Robinson, B.S. *see* Watt, P.J., 231
Rodicio, J.L. *see* Bruguera, M., S47
Rodolakis, A. *see* Buzoni-Gatel, D., 342
Romano, L. *see* Zanetti, A.R., 205
Romanova, Y. *see* Linde, K., 25
Ronco, J. *see* van der Werf, S., 269
Ronnberg, P-R. *see* Eskola, J., 107
Rook, G.M. *see* Stanford, J.L., 525
Rooney, J. *see* Black, R.E., 81
Ruiz, M. *see* Schultz, C.L., 115
Runeberg-Nyman, K. *see* Himanen, J-P., 600

Sack, D.A. *see* Ahmed, Z.U., 153
Sack, D.A. *see* Clemens, J.D., 469
Saeki, S. *see* Ogawa, R., 486
Safary, A. *see* Wiedermann, G., 581
Saiki, I. *see* Maeda,H., 237
Saito, S. *see* Ogawa, R., 486
Sakoh, M. *see* Oka, T., 573
Sakulramrung, R. *see* Poovorawan, Y., 856
Salk, J. Are booster doses of poliovirus vaccine necessary?, 419
Saluzzo, J.F. and Smith, J.F. Use of reassortment viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine, 369
Salva, F. *see* Gonzalez, M.L., 402
Samama, J.P. *see* Muller, S., 308
Samuel, A.R., Ouldridge, E.J., Arrowsmith, A.E.M., Kitching, R.P. and Knowles, N.J. Antigenic analysis of serotype O foot-and-mouth disease virus isolates from the Middle East, 1981 to 1988, 390
Sanders, P.G. *see* Gibson, C.A., 590
Sanpavat, S. *see* Poovorawan, Y., S56
Saris, P. *see* Himanen, J-P., 600
Sarker, M.R. *see* Ahmed, Z.U., 153
Sarvas, M. *see* Himanen, J-P., 600
Sawaguchi, K. *see* Ogawa, R., 486
Saxena, S.N. *see* Bhandari, S.K., 105
Saxena, S.N. *see* Gupta, R.K., 289, 563
Schalen, C. *see* Stjernquist-Desatnik, A., 150
Schats, G.C. *see* Margolis, H.S., 881
Scheiermann, N., Gesemann, M., Maurer, C., Just, M. and Berger, R. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules, S44
Schellekens, H. *see* Fujisawa, Y., 192
Schindel-Kunzel, F. *see* Bock, H.L., 22
Schodel, F., Enders, G., Jung, M-C. and Will, H. Recognition of a hepatitis B virus nucleocapsid T-cell epitope expressed as a fusion protein with the subunit of *Escherichia* heat labile enterotoxin in attenuated salmonellae, 569
Schultz, C.L., Kaufman, B., Hamilton, D., Hartman, A., Ruiz, M., Powell, C. and Berman, S. Cell wall structures which may be important for successful immunization with *Salmonella–Shigella* hybrid vaccines, 115
Schwarz, S. *see* Fescharek, R., 333, 446
Schwenke, S. *see* Masihi, K.N., 159
Seifer, M. *see* Gerlich, W.H., S63
Sekiguchi, S. *see* Maeda, H., 237
Selzer, N.L. *see* Gerber, J.D., 536
Senden, T.F. Response to intradermal hepatis B vaccination: differences between males and females?, 612
Sentrakul, P. *see* Poovorawan, Y., S56
Shafren, D.R. and Tannock, G.A. Development and application of an improved infectivity assay for the standardization of avian encephalomyelitis vaccines, 283
Shahum, E. *see* Therien, H-M., 558
Sharma, A.K. *see* Talwar, G.P., 121
Sharma, S.B. *see* Bhandari, S.K., 105
Sharma, S.B. *see* Gupta, R.K., 289, 563
Sharpes, R.L. *see* Gerber, J.D., 536
Shearman, D.J.C. *see* Forrest, B.D., 209
Sherlock, S. Hepatitis B: the disease, S6
Shimada, K. *see* Hirabayashi, Y., 243
Sinha, A.K. and Pal, S.C. New approach to develop a vaccine design against shigellosis, 410
Slepushkin, A.N. *see* Obrosova-Servoa, N-P., 57
Smith, J.F. *see* Saluzzo, J.F., 369
Snavely, D.B. *see* West, D.J., 111
Sobol, A.V. *see* Kusov, Y.Y., 513
Sotnikov, A.V. *see* Murphy, B.R., 497
Spehner, D. *see* Wild, F., 441
Stanford, J.L., Rook, G.M., Bahr, G.A., Dowlati, Y., Ganapati, R., Ghazi Saidi, K., Lucas, S., Ramu, G., Torres, P., Minh Ly, Ho and Anstey, N. *Mycobacterium vaccae* in immunoprophylaxis and immunotherapy of leprosy and tuberculosis, 525
Steffen, R. Risk of hepatitis B for travellers, S31
Stephenne, J. *see* Wiedermann, G., 581
Stephenne, J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine, S69
Stjernquist-Desatnik, A., Kurl, D.N., Schalen, C. and Christensen, P. Protective effect of heterologous

Gram-positive vaccine against lethal upper respiratory tract infection with type M50 group A streptococci in mice, 150
Storsaeter, J., Hallander, H., Farrington, C.P., Olin, P., Mollby, R. and Miller, E. Secondary analysis of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial, 457
Strachan, E. *see* Cook, R.F., 491
Straub, O.C. *see* Berger, H.G., 213
Sugiura, A. *see* Yamada, A., 553
Sundquist, B. *see* Cook, R.F., 491
Sung, J.L. and Asian Regional Study Group. Hepatitis B virus eradication strategy for Asia, 895
Sureau, P. *see* Joffret, M-L., 385
Suresh, S.K. *see* Talwar, G.P., 121
Suzuki, Y. *see* Tamura, S-I., 479
Svennerholm, A-M. *see* Clemens, J.D., 469

Taira, S. *see* Himanen, J-P., 600
Tajima, T., Thompson, J., Wright, P.F., Kondo, Y., Tollefson, S.J., King, J. and Kapikian, A.Z. Evaluation of a reassortant rhesus rotavirus vaccine in young children, 70
Takafuji, E.T. *see* Bancroft, W.H., S33
Takahashi, T. *see* Maeda, H., 237
Takahashi, Y. *see* Yamada, A., 553
Takala, A. *see* Eskola, J., 107
Takeuchi, K. *see* Yamada, A., 553
Tall, B.D. *see* Herrington, D.A., 353
Talwar, G.P., Zaheer, S.A., Mukherjee, R., Walia, R., Misra, R.S., Sharma, A.K., Kar, A., Mukherjee, H.K., Parida, N.R., Suresh, S.K., Nair, S.K. and Pandey, R.M. Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, *Mycobacterium* w in multibacillary leprosy patients, 121
Tamura, S-I., Funato, H., Hirabayashi, Y., Kikuta, K., Suzuki, Y., Nagamine, T., Aizawa, C., Nakagawa, M. and Kurata, T. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza, 479
Tamura, S. *see* Hirabayashi, Y., 243
Tanabayashi, K. *see* Yamada, A., 553
Tannirundorn, Y. *see* Poovorawan, Y., 856
Tannock, G.A. *see* Shafren, D.R., 283
Tanzi, E. *see* Zanetti, A.R., 205
Tartar, A. *see* Holivet, M., 35
Tesar, M. *see* Berger, H.G., 213
Theobald, K. *see* Bock, H.L., 22
Therien, H-M., Lair, D. and Shahum, E. Liposomal vaccine: influence of antigen association on the kinetics of the humoral response, 558
Thomas, I. *see* Brochier, B., 101
Thompson, J. *see* Tajima, T., 70
Thomssen, R. *see* Gerlich, W.H., 863
Thyagarajan, S.P. *see* Blumberg, B.S., 886
Tinsley, C.R. *see* Heckels, J.E., 225
Titova, I.P. *see* Kusov, Y.Y., 513
Tollefson, S.J. *see* Tajima, T., 70
Tomasic, J. *see* Valinger, Z., 585
Tommassen, J. *see* Agterberg, M., 85, 438
Torres, P. *see* Stanford, J.L., 525
Toukan, A. and Middle East Regional Study. Strategy for the control of hepatitis B virus infection in the Middle East and North Africa, S117
Toyosawa, T. *see* Iida, J., 376
Tramont, E.C. *see* Herrington, D.A., 353
Trescec, A. *see* Valinger, Z., 585
Tsujii, T. *see* Ishizaka, S., 337
Tsukidate, K. *see* Iida, J., 376
Tsvetanov, Y. *see* Linde, K., 25
Tyrrell, D.A.J. *see* Watt, P.J., 231

Usandizaga, M. *see* Gonzalez, M.L., 402

Valette, M. *see* Muller, S., 308
Valinger, Z., Trescec, A. and Tomasic, J. Comparison of immunogenicity of recombinant and plasma derived hepatitis B antigen in guinea pigs, 0
Van Damme, P., Vranckx, R. and Meheus, A. Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down's syndrome, S53
van Drunen Little-van den Hurk, S., Gifford, G.A. and Babuik, L.A. Epitope specificity of the protective immune response induced by individual bovine herpesvirus-1 glycoproteins, 358
Van Eerd, P.M.C.A. *see* Fujisawa, Y., 192
van Loon, M.R. *see* Clemens, J.D., 469
van Maanen, K. *see* Agterberg, M., 438
van Regenmortel, M.H.V. *see* Muller, S., 308
Van de Verg, L. *see* Herrington, D.A., 353
van der Werf, S., Charbit, A., Leclerc, C., Mimic, V., Ronco, J., Girard, M. and Hofnung, M. Critical role of neighbouring sequences on the immunogenicity of the C3 poliovirus neutralization epitope expressed at the surface of recombinant bacteria, 269
van der Zeijst, B.A.M. *see* Kusters, J.G., 605
Vassilev, T. *see* Linde, K., 30
Vaughan, P.R. *see* Macreadie, I.G., 549
Vaux-Peretz, F. and Meignier, B. Comparison of lung histopathology and bronchoalveolar lavage cytology in mice and cotton rats infected with respiratory syncytial virus, 543
Venkateswaran, P.S. *see* Blumberg, B.S., S86
Virji, M. *see* Heckels, J.E., 225
Vranckx, R. *see* Van Damme, P., S53

Walia, R. *see* Talwar, G.P., 121
Ward, C.W. *see* Macreadie, I.G., 549
Watt, P.J., Robinson, B.S., Pringle, C.R. and Tyrrell, D.A.J. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines, 231
Weinmann, W. *see* Barth, R., 41
Wentz, K.R. *see* Marcuse, E.K., 531
West, D.J., Snavely, D.B., Zajac, B.A., Brown, G.W. and Babb, C.J. Development of persistence of antibody in a high risk institutionalized population given plasma-derived hepatitis B vaccine, 111
World Health Organization. Potential use of live viral and bacterial vectors for vaccines, WHO meeting, Geneva, 19–22 June 1989, 425
Wiedermann, G., Ambrosch, F., Kollaritsch, H., Hofmann, H., Kunz, C., D'Hondt, E., Delem, A., Andre, F.E., Safary, A. and Stephenne, J. Safety and immunity of an inactivated hepatitis A vaccine against candidate in healthy adult volunteers, 581
Wild, F., Giraudon, P., Spehner, D., Drillien, R. and Lecocq, J.P. Fowlpox virus recombinant encoding the measles virus fusion protein: protection of mice against fatal measles encephalitis, 441
Will, H. *see* Schodel, F., 569
Willis, M.R. *see* Gibson, C.A., 590
Wright, P.F. *see* Tajima, T., 70
Wyde, P.R. *see* Mbawuike, I.N., 347

Yamada, A., Takeuchi, K., Tanabayashi, K., Hishiyama, M., Takahashi, Y. and Sugiura, A. Differentiation of the mumps vaccine strains from the wild viruses by the nucleotide sequences of the P gene, 553
Yamamoto, A. *see* Yamaya, S.I., 65
Yamamoto, N. *see* Maeda, H., 237
Yamaya, S.I., Yamamoto, A., Komiya, T., Mizuguchi, J. and Matuhasi, T. Preparation of a diphtheria toxin–pullulan conjugate that elicits good IgG antibody production with poor IgE synthesis, 65
Yanagida, N. *see* Ogawa, R., 486
Yeoh, E.K. Hepatitis B virus infection in children, S29
Yoshikawa, M. *see* Ishizaka, S., 337
Yoshioka, Y. *see* Nerome, K., 503
Yunis, S. *see* Clemens, J.D., 469
Yvonnet, B. *see* Coursaget, P., S15

Zaheer, S.A. *see* Talwar, G.P., 121
Zajac, B.A. *see* West, D.J., 111
Zanetti, A.R., Tanzi, E., Pozzi, A., Romano, L. and Bergamini, F. Yeast-derived hepatitis B vaccine in dental students. A three-year follow-up study, 205
Zanetti, C. *see* Joffret, M-L., 385
Zerban, R. *see* Bock, H.L., 22

Subject Index

AIDS: *see* HIV, 3
Acellular vaccine: *see* Pertussis, 172
Acellular: *see* Pertussis, 457
Adamantylamide dipeptide: *see* Influenza, 159
Adjuvant; *see* Influenza, 49, 159
Adjuvant: *see* Diphtheria toxin, 65
Adults: *see* Cholera, 577
Africa, North: *see* Hepatitis B, 917
Africa, sub-Saharan: *see* Hepatitis B, S107
Agglutinin: *see* Pertussis, 600
Antibody persistence: *see* Hepatitis B, S44, S74
Antigenic mapping: *see* Parainfluenza, 75
Antigens: *see* Peptide, 257
Asia: *see* Hepatitis B, S95
Attenuated vaccine: *see* Influenza, 57, 61
Attenuation: *see Salmonella*, 278
Attenuation: *see Shigella flexneri*, 25
Aujeszky's disease: Genetically engineered vaccines for control of Aujeszky's disease (pseudorabies), 420
Avian coronavirus: *see* RNA recombination, 605
Avian encephalomyelitis: Development and application of an improved infectivity assay for the standardization of avian encephalomyelitis vaccines, 283

B subunit: *see* Influenza, 243, 479
Bacillus subtilis: see Pertussis, 600
Bivalent vaccine: *see Salmonella*, 5
Book Reviews, 95, 173, 293, 411
Booster dose: *see* Poliovirus, 419
Breast-milk: *see* Cholera, 469
Bronchoalveolar lavage: *see* Respiratory syncytical virus, 543
Brucella: Brucella suis S2, *Brucella melitensis* Rev. 1 and *Brucella abortus* S19 living vaccines: residual virulence and immunity induced against three *Brucella* species challenge strains in mice, 462

Carboxy-vinylpolymer: *see* Influenza, 573
Children: *see* Hepatitis B, S29
China: *see* Hepatitis A, 523
Cholera toxin: *see* Influenza, 243, 479
Cholera: Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines, 469
Cholera: Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults, 577
Clinical trial: *see* Encephalitis, tick-borne, 22
Clinical trial: *see Shigella flexneri*, 30
Cold-adapted strain: *see* Influenza, 57, 61
Conference Report, 294, 413, 516
Coproantibodies: *see Shigella flexneri*, 30
Coronavirus: *see* RNA recombination, 605
Cost–benefit: *see* Hepatitis B, S81

Delta virus: *see* Hepatitis B, S10, S100
Diphtheria toxin: Preparation of a diphtheria toxin–pullulan conjugate that elicits good IgG antibody production with poor IgE synthesis, 65
Down's syndrome: *see* Hepatitis B, S53

EPI: *see* Hepatitis B, 818
Encephalitis, tick-borne: A new vaccine against tick-borne encephalitis: initial trial in man including a dose response study, 22
Encephalitis: *see* Fowlpox virus, 441
Enteric-coated capsules: *see Salmonella typhi*, 81
Epidemiology: *see* Hepatitis B, 6, 29, 33, 122
Epidemiology: *see* Measles virus, 446
Epitope: *see* Foot-and-mouth disease, 85
Epitope: *see* Hepatitis B, 15, 63
Epitope: *see* Peptide, 257
Epitope: *see* Poliovirus, 269
Equine herpes virus: Protection against lethal equine herpes virus type 1 (subtype 1) infection in hamsters by immune stimulating complexes (ISCOMs) containing the major viral glycoproteins, 491
Escherichia coli: see Foot-and-mouth disease, 85
Escherichia coli: see Hepatitis B, 585
Europe: *see* Hepatitis B, 913

Feline infectious peritonitis: Protection against feline infectious peritonitis by intranasal inoculation of a temperature sensitive FIPV vaccine, 536
Feline leukaemia: Evaluation of immunosuppressive effect and efficacy of an improved-potency feline leukaemia vaccine, 12
Foot-and-mouth disease: International bank for foot-and-mouth disease vaccine: stability studies with virus concentrates and vaccines prepared from them, 473
Foot-and-mouth disease: Isotype response of infected, virus-vaccinated and peptide-vaccinated cattle to foot-and-mouth disease virus, 249
Foot-and-mouth disease: Outer membrane PhoE protein of *Escherichia coli* as a carrier for foreign antigenic determinants: immunogenicity of epitopes of foot-and-mouth disease virus, 85
Foot-and-mouth disease: Protection of guinea-pigs against foot-and-mouth disease virus by immunization with a PhoE–FMDV hybrid protein, 438
Formaldehyde-inactivated: *see* Hepatitis A, 523
Formalin inactivation: *see* Respiratory syncytical virus, 497, 543
Fowlpox virus: Fowlpox virus recombinant encoding the measles virus fusion protein: protection of mice against fatal measles encephalitis, 441
Fowlpox virus: Recombinant fowlpox viruses inducing protective immunity against Newcastle disease and fowlpox viruses, 486

Glutaraldehyde-inactivated: *see* Pertussis, 600
Glycoprotein: *see* Equine herpes virus, 491
Glycoprotein: *see* Respiratory syncytial virus, 497

H2-strain: *see* Hepatitis A, 523
HIV: AIDS vaccine research in the UK, 3
Haemagglutinin: *see* Influenza, 479
Haemagglutinin A: *see* Influenza, 49
Haemagglutinin, filamentous: *see* Pertussis, 289
Haemodialysis: *see* Hepatitis B, S47
Health care workers: *see* Hepatitis B, S24
Hepatitis A: Development of live, attenuated hepatitis A vaccine (H2-strain), 523
Hepatitis A: Characteristics of inactivated hepatitis A vaccine prepared from virus propagated in heteroploid continuous monkey cell line, 513
Hepatitis A: Safety and immunity of an inactivated hepatitis A vaccine against candidate in healthy adult volunteers, 581
Hepatitis B: Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage, S56
Hepatitis B: Comparison of immunogenicity of recombinant and plasma derived hepatitis B antigen in guinea pigs, 585
Hepatitis B: Controlling hepatitis B virus transmission in North America, S122
Hepatitis B: Development and production aspects of a recombinant yeast-derived hepatitis B vaccine, S69
Hepatitis B: Development of recommendations for control of hepatitis B virus infections: the role of cost analysis, S81
Hepatitis B: Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA

hepatitis B vaccine in haemodialysis patients, S47
Hepatitis B: Epidemiology and eradication strategy for hepatitis B in Europe, S113
Hepatitis B: Hepatitis B in Latin America: epidemiological patterns and eradication strategy, S10
Hepatitis B: Hepatitis B infection in sub-Saharan Africa, S17
Hepatitis B: Hepatitis B surface antigen reactivity in man due to a new variant of hepatitis B virus, S15
Hepatitis B: Hepatitis B virus and primary hepatocellular carcinoma: treatment of HBV carriers with *Phyllanthus amarus*, S86
Hepatitis B: Hepatitis B virus eradication strategy for Asia, S95
Hepatitis B: Hepatis B virus infection and health care workers, S24
Hepatitis B: Hepatitis B virus infection in children, S29
Hepatitis B: Hepatitis B: global importance and and need for control, S18
Hepatitis B: Hepatitis B: the disease, S6
Hepatitis B: Hepatitis B: transmission by sexual contact and needle sharing, S37
Hepatitis B: Hepatitis delta virus as a global health problem, S10
Hepatitis B: Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down's syndrome, S53
Hepatitis B: Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine, S74
Hepatitis B: Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules, S44
Hepatitis B: Protective efficacy of a recombinant DNA vaccine against hepatitis B in male homosexuals: results at 36 months, S50
Hepatitis B: Protective potential of hepatitis B virus antigens other than the S gene protein, S63
Hepatitis B: Recognition of a hepatitis B virus nucleocapsid T-cell epitope expressed as a fusion protein with the subunit of *Escherichia* heat labile enterotoxin in attenuated salmonellae, 569
Hepatitis B: Risk of hepatitis B for travellers, S31
Hepatitis B: Strategy for the control of hepatitis B virus infection in the Middle East and North Africa, S117
Hepatitis B: The military and hepatitis B, S33
Hepatitis B; WHO strategy for the global elimination of new cases of hepatitis B, S129
Hepatocellular carcinoma: *see* Hepatitis B, S86, S95
Herpesvirus: *see* Pseudorabies, 286
Heterosexual: *see* Hepatitis B, S37
Homosexual: *see* Hepatitis B, S37, S50
Humoral response: *see* Liposomal vaccine, 558
Hybrid protein: *see* Foot-and-mouth disease, 438

ISCOM: *see* Equine herpes virus, 491
Immune globulin: *see* Hepatitis B, S56
Immunogenicity: *see* Hepatitis B, 853
Immunogenicity: *see* Polyvalent vaccine, 35
Immunosuppression: *see* Feline leukaemia, 12
Immunosuppression: *see* Rabies, 172
Inactivated vaccine virus: *see* Encephalitis, tick-borne, 22
Infectious bronchitis virus: *see* RNA recombination, 605
Infectious bursal disease virus: Passive protection against infectious bursal disease virus by viral VP2 protein, 549
Infectivity assay: *see* Avian encephalomyelitis, 283
Influenza: Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination, 243
Influenza: Development of a new type of influenza subunit vaccine made by muramyldipeptide-liposome: enhancement of humoral and cellular immune responses, 503
Influenza: Effect of immunomodulator adamantylamide dipeptide on antibody response to influenza subunit vaccines and protection against aerosol influenza infection, 159
Influenza: Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation, 49
Influenza: Evaluation in children of cold-adapted influenza B live attenuated intranasal vaccine prepared by reassortment between wild-type B/Ann Arbor/1/86 and cold-adapted B/Leningrad/14/55 viruses, 57
Influenza: Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza, 479
Influenza: Influenza vaccine: enhancement of immune response by application of carboxy-vinylpolymer, 573
Influenza: Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates, 61
Interleukin: *see Vaccinia* vector, 17
Intranasal immunization: *see* Feline infectious peritonitis, 536
Intranasal immunization: *see* Influenza, 573
Intravenous drug users: *see* Hepatitis B, S37

Killed vaccine: *see* Poliovirus, 443
Kinetics: *see* Liposomal vaccine, 558

Latin America: *see* Hepatitis B, 900
Leprosy: *see Mycobacterium vaccae*, 525
Liposomal vaccine: Liposomal vaccine: influence of antigen association on the kinetics of the humoral response, 558
Liposome: *see* Influenza, 503
Live-attenuated vaccine: *see Brucella*, 462
Lung histopathology: *see* Respiratory syncytical virus, 543

Measles virus: *see* Fowlpox virus, 441
Measles virus: Measles–mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects, 446
Middle East: *see* Hepatitis B, S117
Military personnel: *see* Hepatitis B, S33
Monoclonal antibodies: *see* Parainfluenza, 75
Mumps virus: Differentiation of the mumps vaccine strains from the wild viruses by the nucleotide sequences of the P gene, 553
Mumps virus: *see* Measles virus, 446
Muramyldipeptide: *see* Influenza, 503
Mutant: *see Salmonella*, 278
Mutant: *see Salmonella typhi*, 263
Mycobacterium vaccae: *Mycobacterium vaccae* in immunoprophylaxis and immunotherapy of leprosy and tuberculosis, 525

Neurovirulence: *see* Yellow fever, 590
Newcastle disease: *see* Fowlpox virus, 486
Nucleotide sequences: *see* Mumps virus, 553

Oral attenuated vaccine: *see* Cholera, 577

P gene: *see* Mumps virus, 553
Parainfluenza: Antibody response in children to antigenic sites on human PIV-3 HN: correlation with known epitopes mapped by monoclonal antibodies, 75
Passive immunity test: *see* Foot-and-mouth disease, 249
Patent Report, 92, 169, 290, 406, 510, 609
Peptide: Defining minimal requirements for antibody production of peptide antigens, 257
Pertussis: Expression of pertussis toxin subunit S4 as an intracytoplasmic protein in *Bacillus subtilis*, 600
Pertussis: Immunogenicity of glutaraldehyde inactivated pertussis vaccine, 0
Pertussis: *see* Pertussis vaccine controversy, 172
Pertussis: Protection of mice inoculated with purified pertussis toxin and filamentous haemagglutinin against intracerebral challenge with live *Bordetella pertussis*, 289
Pertussis: Secondary analysis of the efficacy of two acellular pertussis

vaccines evaluated in a Swedish phase III trial, 457
Phase III trial vaccine: *see* Pertussis, 457
PhoE protein: *see* Foot-and-mouth disease, 85, 438
Phyllanthus amarus: see Hepatitis B, S86
Plasma-derived: *see* Hepatitis B, 585
Poliomyelitis: Poliomyelitis serosurveillance and immunization for elderly people in otherwise efficiently immunized areas, 514
Poliovirus: Are booster doses of poliovirus vaccine necessary?, 419
Poliovirus: Critical role of neighbouring sequences on the immunogenicity of the C3 poliovirus neutralization epitope expressed at the surface of recombinant bacteria, 269
Poliovirus: Polio immunity to killed vaccine: an 18-year follow-up, 443
Polyvalent vaccine: Polyvalent synthetic vaccines: relationship between T epitopes and immunogenicity, 35
Postexposure: *see* Rabies, 41
Prophylaxis: *see* Rabies, 172
Pseudorabies: Recombination *in vivo* of pseudorabies vaccine strains to produce new virus strains, 286
Pseudorabies: *see* Aujeszky's disease, 420
Pullulan: *see* Diphtheria toxin, 65
Purified chick embryo cell: *see* Rabies, 41

RNA recombination: Sequence evidence for RNA recombination in field isolates of avian coronavirus IBV, 605
Rabies: Dangers of immunosuppressive treatments in postexposure rabies prophylaxis, 172
Rabies: Purified chick-embryo-cell (PCEC) rabies vaccine: its potency performance in different test systems and in humans, 41
Reassortant: *see* Rotavirus, 70
Recombinant DNA: *see* Hepatitis B, S44
Recombinant: *see* Aujeszky's disease, 420
Recombinant: *see* Fowlpox virus, 441, 486
Recombinant: *see* Hepatitis B, S18, S47, S50, S56, S63, S69, S74, 585
Recombinant: *see* Poliovirus, 269
Recombinant: *see* Pseudorabies, 286
Recombinant: *see Salmonella*, 5
Recombinant: *see* Vaccinia vector, 17
Respiratory syncytical virus: Comparison of lung histopathology and bronchoalveolar lavage cytology in mice and cotton rats infected with respiratory syncytial virus, 543
Respiratory syncytial virus: Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytia virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization, 497
Respiratory syntical virus: *see* Recombinant, 164
Rotavirus: Evaluation of a reassortant rhesus rotavirus vaccine in young children, 70

Salmonella typhi: Efficacy of one or two doses of Ty21a *Salmonella typhi* vaccine in enteric-coated capsules in a controlled field trial, 81
Salmonella typhi: In vitro characterization of *Salmonella typhi* mutant strains for live oral vaccines, 263
Salmonella vector: *see* Hepatitis B, 569
Salmonella: Salmonella-based vaccines, 5
Salmonella: Stable *Salmonella* live vaccine strains with two or more attenuating mutations and any desired level of attenuation, 278
Secretory immunity: *see* Cholera, 469
Serum markers: *see* Hepatitis B, S6
Shigella flexneri: Live *Shigella flexneri* 2a and *Shigella sonnei* I vaccine candidate strains with two attenuating markers I. Construction of vaccine candidate strains with retained invasiveness but reduced intracellular multiplication, 25
Shigella flexneri: Live *Shigella flexneri* 2a and *Shigella sonnei* I vaccine candidate strains with two attenuating markers. II. Preliminary results of vaccination of adult volunteers and children aged 2–17 years, 30
Shigella sonnei: see Shigella flexneri, 25, 30
Side effects: *see* Measles virus, 446
Sodium aurothiomalate: *see* Yellow fever, 590
Stability: *see* Foot-and-mouth disease, 473
Surface antigen: *see* Hepatitis B, S15

T epitope: *see* Polyvalent vaccine, 35
T-cell: *see* Hepatitis B, 569
Temperature sensitive: *see* Feline infectious peritonitis, 536
Toxin subunit S4: *see* Pertussis, 600
Toxin; *see* Pertussis, 289
Transmission: *see* Hepatitis B, S122
Trial: *see* Hepatitis A, 581
Tuberculosis: *see Mycobacterium vaccae*, 525
Typhoid fever: *see Salmonella typhi*, 81

VP2 protein: *see* Infectious bursal disease virus, 549
Vaccinia vector: Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2, 17
Vaccinia vector: *see* Recombinant, 164
Viraemia: *see* Feline leukaemia, 12
Virus: *see* Feline infectious peritonitis, 536

Woodchuck hepatitis virus: *see* Hepatitis B, 886

Yellow fever: Effect of administration of sodium aurothiomalate on the virulence of yellow fever viruses in adult mice, 590